Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)

被引:0
作者
Mark Clemons
Sasha Mazzarello
John Hilton
Anil Joy
Julie Price-Hiller
Xiaofu Zhu
Shailendra Verma
Anne Kehoe
Mohammed FK Ibrahim
Marta Sienkiewicz
Carol Stober
Lisa Vandermeer
Brian Hutton
Ranjeeta Mallick
Dean Fergusson
机构
[1] The University of Ottawa,Department of Medicine, Division of Medical Oncology, The Ottawa Hospital Cancer Centre
[2] The Ottawa Hospital Research Institute,Cancer Research Program
[3] The Ottawa Hospital Research Institute,Clinical Epidemiology Program
[4] Cross Cancer Institute,Division of Medical Oncology, Department of Oncology, University of Alberta
来源
Supportive Care in Cancer | 2019年 / 27卷
关键词
Integrated consent model; Breast cancer; Febrile neutropenia; Filgrastim; Ciprofloxacin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1345 / 1354
页数:9
相关论文
共 177 条
[1]  
Jones SE(2006)Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer J Clin Oncol 24 5381-5387
[2]  
Savin MA(2012)Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis Support Care Cancer: official journal of the Multinational Association of Supportive Care in Cancer 20 2523-2530
[3]  
Holmes FA(2015)Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 33 3199-3212
[4]  
O'Shaughnessy JA(2011)2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours Eur J Cancer 47 8-32
[5]  
Blum JL(2013)Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia Curr Oncol 20 e171-e179
[6]  
Vukelja S(2017)Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review Breast Cancer Res Treat 161 1-10
[7]  
McIntyre KJ(2018)Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients Support Care Cancer : official journal of the Multinational Association of Supportive Care in Cancer 26 2323-2331
[8]  
Pippen JE(2016)Novel methodology for comparing standard-of-care interventions in patients with Cancer J Oncol Pract 12 e1016-e1024
[9]  
Bordelon JH(2017)A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer Breast Cancer Res Treat 168 371-379
[10]  
Kirby R(2001)Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis Exp Biol Med (Maywood) 226 78-84